According to the report, the Asia Pacific Theranostics Market Size was valued at USD 19.61 Million in 2021 and is also predicted to reach USD 38.14 Million by 2026, growing at a CAGR of 14.23% during the forecast period 2021 to 2026.
Theranostics is expected to increase fast as cancer incidence continues to rise and side-effects of procedures like chemotherapy continue to be difficult for practitioners. Furthermore, because recovery is often slow and requires time away from patients' daily routines, post-cancer care promises lucrative growth.
Rising disposable income, a significant population, and more access to healthcare are projected to generate a substantial increase soon in the Asia Pacific theranostics industry. As we look ahead, Europe's growing older population, technologically improved healthcare systems, and possibilities like universal care are projected to fuel significant development. In addition, the global theranostics market is being driven by the rising prevalence of life-threatening and chronic diseases, the demand for new chemotherapeutic therapies, and better disease diagnostics.
Furthermore, the growing potential of therapeutically functional nanomaterials in biological imaging and therapy is likely to drive market expansion. Due to rising awareness and use of companion diagnostics, particularly for cancers, the Asia-Pacific theranostics market is predicted to increase over the forecast period rapidly. Global firms are also putting a lot of effort into developing partnerships and collaborations with regional players to introduce strategic products and increase product sales margins.
Theranostics is the combination of diagnostics and medication therapy to speed up the creation of a more effective and less expensive drug. Cancer has emerged as a significant worry for the healthcare sector. Developing an effective medicine with minimal side effects has become an urgent requirement, requiring close collaboration between drug developers and the diagnostic industry. Theranostics is a new discipline attracting much attention from regulatory organizations and the healthcare industry.
The high costs of treatment and the fact that it is still experimental are expected to be essential impediments to its development. Furthermore, healthcare prices and a lack of information about post-cancer therapies are expected to be roadblocks in countries like the Asia Pacific.
This research report on the APAC Theranostics Market has been segmented and sub-segmented into the following categories.
By Disease Type:
By Technology:
By End-User:
By Country:
Geographically, the Asia Pacific is the world's second-largest market for theranostics. In this region, China theranostics market and India theranostics market are the developing nations among the public due to rapidly improving medical infrastructure, increasing medical tourism, newer rules implemented by governing bodies, and increased awareness; the APAC region is predicted to grow at the fastest rate.
In addition, Theranostics market growth is expected to be aided by better collaboration between medication and diagnostics companies. Another significant driver fueling the development of the global theranostics market is the reduction in costs and time necessary for medical trials supervised by pharmaceutical industries. In addition, the worldwide theranostics industry is being driven by the rising incidence of cardiovascular and cancer diseases.
Furthermore, ongoing research initiatives in these domains contribute significantly to market growth. Again, the growing number of strategic alliances and partnerships is expected to move the overall industry forward at a rapid rate. The global increase in the development of novel companion diagnostic tests, the mounting adoption of companion diagnostic tests by end-users, the increasing collaborations and partnerships by prominent market participants to develop innovative companion diagnostics, and the rising burden of chronic diseases are all factors driving the market forward.
KEY MARKET PLAYERS
Top companies leading in the APAC Theranostics Market profiled in the report are Abbott Laboratories, AmeriPath, Dickinson and Company, BIOTEC Laboratories, Dade Behring, Dianon Systems, Dynacare Laboratories, Enterix, Focus Diagnostics, Pfizer, and Beckman Coulter.,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Disease Type
5.1.1 Introduction
5.1.2 Neurological Disorders
5.1.3 Cardiovascular Diseases
5.1.4 Cancers
5.1.5 Others
5.1.6 Y-o-Y Growth Analysis, By Disease Type
5.1.7 Market Attractiveness Analysis, By Disease Type
5.1.8 Market Share Analysis, By Disease Type
5.2 By Technology
5.2.1 Introduction
5.2.2 Polymerase Chain Reaction (PCR)
5.2.3 Immunohistochemistry
5.2.4 In Situ Hybridization
5.2.5 Sequencing
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Technology
5.2.8 Market Attractiveness Analysis, By Technology
5.2.9 Market Share Analysis, By Technology
5.3 By End User
5.3.1 Hospitals
5.3.2 Diagnostics Laboratories
5.3.3 Others
5.3.4 Y-o-Y Growth Analysis, By End User
5.3.5 Market Attractiveness Analysis, By End User
5.3.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Disease Type
6.1.3.3 By Technology
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Disease Type
6.1.4.3 By Technology
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Disease Type
6.1.5.3 By Technology
6.1.5.4 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AmeriPath
8.3 Dickinson and Company
8.4 BIOTEC Laboratories
8.5 Dade Behring
8.6 Dianon Systems
8.7 Dynacare Laboratories
8.8 Enterix
8.9 Focus Diagnostics
8.10 Pfizer
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
